Evidence map›Paper›PMID 34519855›Full record

ArticleApplied microbiology and biotechnology2021

Cell culture-based production of defective interfering influenza A virus particles in perfusion mode using an alternating tangential flow filtration system.

Marc D Hein, Anshika Chawla, Maurizio Cattaneo, Sascha Y Kupke, Yvonne Genzel, Udo Reichl

Open access · hybridAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Marc D HeinChair of Bioprocess Engineering, Otto-Von-Guericke-University Magdeburg, Magdeburg, Germany.
Anshika ChawlaBioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany.
Maurizio CattaneoArtemis Biosystems, Cambridge, MA, USA.
Sascha Y KupkeBioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany. kupke@mpi-magdeburg.mpg.de.
Yvonne GenzelBioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany. genzel@mpi-magdeburg.mpg.de.ORCID http://orcid.org/0000-0002-2652-5943
Udo ReichlChair of Bioprocess Engineering, Otto-Von-Guericke-University Magdeburg, Magdeburg, Germany.
Max Planck Institute for Dynamics of Complex Technical Systems · DEArtemis (United States) · USOtto-von-Guericke-Universität Magdeburg · DE

Funding

Defense Advanced Research Projects Agency W911NF-17-2-0012
6 · The paper itself

Abstract

Respiratory diseases including influenza A virus (IAV) infections represent a major threat to human health. While the development of a vaccine requires a lot of time, a fast countermeasure could be the use of defective interfering particles (DIPs) for antiviral therapy. IAV DIPs are usually characterized by a large internal deletion in one viral RNA segment. Consequentially, DIPs can only propagate in presence of infectious standard viruses (STVs), compensating the missing gene function. Here, they interfere with and suppress the STV replication and might act "universally" against many IAV subtypes. We recently reported a production system for purely clonal DIPs utilizing genetically modified cells. In the present study, we established an automated perfusion process for production of a DIP, called DI244, using an alternating tangential flow filtration (ATF) system for cell retention. Viable cell concentrations and DIP titers more than 10 times higher than for a previously reported batch cultivation were observed. Furthermore, we investigated a novel tubular cell retention device for its potential for continuous virus harvesting into the permeate. Very comparable performances to typically used hollow fiber membranes were found during the cell growth phase. During the virus replication phase, the tubular membrane, in contrast to the hollow fiber membrane, allowed 100% of the produced virus particles to pass through. To our knowledge, this is the first time a continuous virus harvest was shown for a membrane-based perfusion process. Overall, the process established offers interesting possibilities for advanced process integration strategies for next-generation virus particle and virus vector manufacturing.Key points• An automated perfusion process for production of IAV DIPs was established.• DIP titers of 7.40E + 9 plaque forming units per mL were reached.• A novel tubular cell retention device enabled continuous virus harvesting.

Indexed as

Influenza A virusCell Culture TechniquesHumansPerfusionAlternating tangential flow filtration (ATF)AntiviralBioreactorCell culture–based productionDefective interfering particles (DIPs)Influenza A virusPerfusion cultivation

Identifiers

PMID34519855
PMCPMC8437742
OpenAlexW3200137906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.